Evome Medical Technologies Inc.
EVMT.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -137.82% | -100.95% | -158.61% | -213.61% | 129.66% |
| Total Depreciation and Amortization | -66.06% | -- | 11.10% | -932.26% | 305.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 101.23% | 343.87% | 39.43% | 170.01% | -159.75% |
| Change in Net Operating Assets | 238.31% | -- | 409.25% | 228.43% | 35.96% |
| Cash from Operations | 246.02% | -- | 25.46% | -27.44% | 63.71% |
| Capital Expenditure | 84.18% | -- | 58.64% | 104.13% | -5.27% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 100.00% | 69.13% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 98.54% | -- | 58.64% | 101.52% | 66.99% |
| Total Debt Issued | 281.01% | -- | -- | 17.79% | -137.42% |
| Total Debt Repaid | -822.64% | -- | 32.56% | 82.79% | 34.84% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -680.15% | -- | -109.93% | 72.43% | -108.69% |
| Foreign Exchange rate Adjustments | 9.15% | -- | 103.89% | 413.87% | 733.85% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 112.62% | -- | -138.95% | 97.66% | 50.32% |